REGENERON PHARMACEUTICALS, INC. (REGN) Earnings
REGENERON PHARMACEUTICALS, INC.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Next earnings (estimated)
Around Oct 27, 2026
From past filing pattern
Get notified when REGN reports →Last reported earnings
Jul 30, 2026
From the latest earnings 8-K
Revenue · FY2025
$14.34B
▲ 1.0%YoY
Diluted EPS · FY2025
$41.48
▲ 8.2%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from REGN's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $14.34B | $4.50B | — | $41.48 | $4.08B | 24.9% | +1.0% |
| FY2024 | $14.20B | $4.41B | — | $38.34 | $3.66B | 28.1% | +8.3% |
| FY2023 | $13.12B | $3.95B | — | $34.77 | $1.41B | 30.9% | +7.8% |
| FY2022 | $12.17B | $4.34B | — | $38.22 | $4.42B | 38.9% | -24.3% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Jul 30, 2026 | 8-K (2.02) | 0000872589-26-000023EDGAR |
| Jul 6, 2026 | 8-K (2.02) | 0001104659-26-080562EDGAR |
| Apr 29, 2026 | 8-K (2.02) | 0000872589-26-000014EDGAR |
| Apr 8, 2026 | 8-K (2.02) | 0001104659-26-040661EDGAR |
| Jan 30, 2026 | 8-K (2.02) | 0000872589-26-000004EDGAR |
| Jan 12, 2026 | 8-K (2.02) | 0001104659-26-002691EDGAR |
| Oct 28, 2025 | 8-K (2.02) | 0000872589-25-000026EDGAR |
| Oct 6, 2025 | 8-K (2.02) | 0001104659-25-096921EDGAR |
Never miss a REGN filing.
Get an email when REGN files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Sep 16, 2026Source: SEC EDGAR.